Zoran Andrić

Zoran Andrić

Auto-generated profile, based on publicly available information

Zoran Andrić

Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia. 3

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Clinical Lung Cancer
Verified
Journal Article
Open access
JWJared Weiss
Jared Weiss
JGJerome Goldschmidt
Jerome Goldschmidt
ZAZoran Andric
Zoran Andric
KDKonstantin H. Dragnev
Konstantin H. Dragnev
CGChad Gwaltney
Chad Gwaltney
DDDavey Daniel
Davey Daniel
Chemotherapy-induced myelosuppression (CIM) and its sequalae cause significant side effects and harm to quality of life. Trilaciclib is an intravenous CDK4/6 inhibitor that is administered prior to chemotherapy to protect hematopoietic stem and progenitor cells from chemotherapy-induced damage (myeloprotection). Data from three randomized, double-blind, placebo-controlled studies (NCT02499770, NCT03041311, and NCT02514447) were pooled to evaluate the effects of trilaciclib administered prior to standard-of-care chemotherapy (first-line etoposide plus carboplatin [E/P], first-line E/P plus atezolizumab, and second-/third-line topotecan) in patients with extensive-stage small cell lung cancer (ES-SCLC). The primary endpoints were duration of severe neutropenia (absolute neutrophil count < 0.5 × 109 cells/L) in cycle 1 and occurrence of severe neutropenia. Additional prespecified endpoints further assessed the effect of trilaciclib on myeloprotection, health-related quality of life (HRQoL), antitumor efficacy, and safety. Of 242 randomized patients, 123 received trilaciclib and 119 received placebo. Compared with placebo, administration of trilaciclib prior to chemotherapy resulted in significant decreases in most measures of multilineage CIM. The reduction in hematologic toxicity translated into the reduced need for supportive care interventions and hospitalizations due to CIM or sepsis and improvements in HRQoL domains related to the protected cell lineages, including fatigue, physical wellbeing, and functional wellbeing. Antitumor efficacy was similar for patients receiving trilaciclib or placebo. Administering trilaciclib prior to chemotherapy resulted in clinically meaningful reductions in CIM and its consequences and improved patient HRQoL, with no impact on the antitumor efficacy of three individual chemotherapy regimens used in the first- or second-/third-line treatment of ES-SCLC.

19 July 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JTJoshua Tobias
Joshua Tobias
MMMarina Maglakelidze
Marina Maglakelidze
ZAZoran Andrić
Zoran Andrić
DRDinara Ryspayeva
Dinara Ryspayeva
IBIurie Bulat
Iurie Bulat
UWUrsula Wiedermann
Ursula Wiedermann
Purpose: A multicenter, randomized, open-label, phase II study (HERIZON; NCT02795988) was conducted to evaluate the clinical and immunologic efficacy of HER-Vaxx (IMU-131), a B-cell, peptide-based vaccine targeting HER2 overexpressed in 6% to 30% of gastroesophageal adenocarcinomas (GEA). Patients and Methods: Patients (n = 36) with GEA were treated with standard-of-care chemotherapy (n = 17) or HER-Vaxx plus chemotherapy (n = 19), using the recommended phase 2 dose for the vaccine. Overall survival (OS; primary endpoint), safety, progression-free survival (PFS), clinical response (secondary endpoints), and vaccine-induced HER2-specific antibody levels in serum and correlation with tumor response rates (exploratory endpoints) were investigated. Results: A 40% OS benefit [HR, 0.60; median OS, 13.9 months; 80% confidence interval (CI), 7.52–14.32] for patients treated with HER-Vaxx plus chemotherapy compared with OS of 8.31 months (80% CI, 6.01–9.59) in patients that received chemotherapy alone. A 20% PFS difference was obtained for the vaccination arm (HR, 0.80; 80% CI, 0.47, 1.38). No additional toxicity due to HER-Vaxx was observed. The vaccine-induced high levels of HER2-specific total IgG and IgG1 antibodies (P < 0.001 vs. controls) that significantly correlated with tumor reduction (IgG, P = 0.001; IgG1, P = 0.016), had a significant capacity in inhibiting phosphorylation of the intracellular HER2-signaling pathways, mediated antibody-dependent cellular cytotoxicity, and decreased immunosuppressive FOXP3+ regulatory T cells. Conclusions: HER-Vaxx plus standard chemotherapy exhibits an excellent safety profile and improves OS. Furthermore, vaccine-induced immune response was significantly associated with reduced tumor size compared with standard-of-care chemotherapy. The presented vaccination approach may substitute for treatment with trastuzumab, upon unavailability or toxicity, based on further evidence of equivalent treatment efficacy.

1 October 2021 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
JBJelica Bjekić-Macut
Jelica Bjekić-Macut
TVTamara Vukašin
Tamara Vukašin
ZVZelija Velija-Ašimi
Zelija Velija-Ašimi
ABAzra Bureković
Azra Bureković
Marija ZdravkovićMarija Zdravković
Marija Zdravković
George MastorakosGeorge Mastorakos
George Mastorakos
Polycystic ovary syndrome (PCOS) is a frequent endocrine disease in women during the reproductive period. It is considered a complex metabolic disorder with long-term metabolic, as well as reproductive consequences. Main pathophysiological pathways are related to the increased androgen levels and insulin resistance. Nowadays, genetic origins of PCOS are acknowledged, with numerous genes involved in the pathogenesis of hyperandrogenemia, insulin resistance, inflammation, and disturbed folliculogenesis. Rotterdam diagnostic criteria are most widely accepted and four PCOS phenotypes have been recognized. Metabolic abnormalities are more common in phenotypes 1 and 2. Women with classic PCOS are more obese and typically have the central type of obesity, more prevalently displaying dyslipidemia, insulin resistance, and metabolic syndrome that could be associated with an increased risk of cardiovascular complications during life. Heterogeneity of phenotypes demands an individualized approach in the treatment of women with PCOS. Metabolic therapies involve a lifestyle intervention followed by the introduction of insulin sensitizers including metformin and inositols, glucagon-like peptide 1 receptor agonists (GLP-1 RA), as recently sodium-glucose cotransporter-2 (SGLT2) inhibitors. The addition of an insulin sensitizer to the standard infertility therapy such as clomiphene citrate improves ovulation and pregnancy rates. Our current review analyzes the contemporary knowledge of PCOS etiology and etiopathogenesis, its cardiometabolic risks and their outcomes, as well as therapeutic advances for women with PCOS.

22 September 2022 in Future Oncology
Verified
Journal Article
Open access
SGShom Goel
Shom Goel
ATAntoinette R Tan
Antoinette R Tan
HRHope Rugo
Hope Rugo
PAPhilippe Aftimos
Philippe Aftimos
ZAZoran Andrić
Zoran Andrić
JOJoyce O’sHaughnessy
Joyce O’sHaughnessy
Triple-negative breast cancer (TNBC) is an aggressive malignancy for which cytotoxic chemotherapy remains the backbone of treatment. Trilaciclib is an intravenous cyclin-dependent kinase 4/6 inhibi... Tweetable abstract Recruiting! PRESERVE 2: a randomized, phase III placebo-controlled trial assessing trilaciclib prior to first-line chemotherapy in patients with advanced or metastatic triple-neg...


13 September 2024
Verified
Other
Open access
JTJoshua Tobias
Joshua Tobias
MMMarina Maglakelidze
Marina Maglakelidze
ZAZoran Andrić
Zoran Andrić
DRDinara Ryspayeva
Dinara Ryspayeva
IBIurie Bulat
Iurie Bulat
UWUrsula Wiedermann
Ursula Wiedermann
Supplementary Figure S9. Correlation between the induced levels of HER2-specific IgG antibodies, and their binding to HER2-expressing cells and intracellular phosphorylation inhibition.